Advertisement

Rituximab-associated neuropathy: About two cases

Published:March 17, 2020DOI:https://doi.org/10.1016/j.ejim.2020.03.011
      Rituximab is a type I anti-CD20 monoclonal antibody, which is primarily used for treating non-Hodgkin's B cell lymphoma [
      • Feugier P.
      A review of Rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
      ]. Clinical efficacy, safety, and modulating effects on normal, malignant pre-B and mature B cells have been reported [
      • Cravedi P.
      Rituximab in membranous nephropathy: not all studies are created equal.
      ]. It is also used off label in the treatment of several autoimmune diseases. Common side effects are infusion-related reactions, such as fever, chills, and shivering, which occur frequently after the first infusion and usually related to cytokines release [
      • Bayer G
      • et al.
      Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: a French nationwide study.
      ]. Other side effects are less frequent but increasingly reported. Here we present 2 cases of Rituximab related neuropathy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Feugier P.
        A review of Rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
        Future Oncol. 2015; 11: 1327-1342
        • Cravedi P.
        Rituximab in membranous nephropathy: not all studies are created equal.
        Nephron. 2017; 135: 46-50
        • Bayer G
        • et al.
        Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: a French nationwide study.
        Eur J Intern Med. 2019; 67: 59-64
        • Vollenhoven R.F.van
        • Fleischmann R.M.
        • Furst D.E.
        • Lacey S.
        • Lehane P.B.
        Longterm Safety of Rituximab: final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years.
        J Rheumatol. 2015; 42: 1761-1766
        • Edwards IR
        • Biriell C.
        Harmonisation in Pharmacovigilance.
        Drug Safety. 1994; 10: 93-102
        • Mavragani C.P.
        • et al.
        A case of reversible posterior leucoencephalopathy syndrome after Rituximab infusion.
        Rheumatology (Oxford). 2004; 43: 1450-1451
        • Galassi G.
        • Testa F.
        • Bianchi F.
        • Cappelli G.
        • Chiari A.
        Acute demyelinating neuropathy associated with Rituximab treatment in a patient with relapsing nephrotic syndrome.
        CEN Case Rep. 2017; 6: 215-216
        • Weiss M.D.
        • Becker P.
        Paradoxical worsening of anti–myelin-associated glycoprotein polyneuropathy following Rituximab.
        Muscle Nerve. 2014; 49: 457-458
        • Mauri C.
        • Bosma A.
        Immune regulatory function of B cells.
        Annu Rev Immunol. 2012; 30: 221-241
        • Gironi M
        • et al.
        Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with Rituximab.
        Haematologica. 2006; 91 (ECR17)